What is Enliven Therapeutics's PP&E sale proceeds?

Enliven Therapeutics (ELVN) reported PP&E sale proceeds of $53.25K in Q4 2025.

What does PP&E sale proceeds mean?

Cash received from selling property, plant, and equipment no longer needed for operations.

Enliven Therapeutics ELVN PP&E Sale Proceeds

PP&E Sale Proceeds at other companies

MYR GroupMYRG

$954K-56.2%

BeldenBDC

$0-100%

RepligenRGEN

$0-100%

UnifirstUNF

$188K+172%

BalchemBCPC

$2K—

Herc HoldingsHRI

$13M+225%

Other financials

Income statement

See full

Operating income-$27.8M+12.2%

Net income-$23.6M+17.2%

EPS (diluted)-$0.38+33.3%

Balance sheet

See full

Cash & equivalents$132.2M+30.0%

Total debt$302.0K-56.9%

Total equity$453.4M+57.3%

Total assets$464.9M+53.6%

Cash flow

See full

Operating cash flow-$19.3M+20.0%

CapEx--100%

Free cash flow-$19.3M+20.1%

Valuation

See full

Market cap$3.47B+143%

Enterprise value$3.34B+156%

Returns & leverage

See full

Return on equity-26.6%-3.5pp

Debt / equity0×0.0×

Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Enliven Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's pp&e sale proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enliven Therapeutics's PP&E sale proceeds?: Enliven Therapeutics (ELVN) reported PP&E sale proceeds of $53.25K in Q4 2025.
What does PP&E sale proceeds mean?: Cash received from selling property, plant, and equipment no longer needed for operations.